Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Subjects With High Grade Primary CNS Malignancies

Next Previous
X
Search
Trial Profile

Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Subjects With High Grade Primary CNS Malignancies

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications CNS cancer; Diffuse intrinsic pontine glioma; Ependymoma; Glioma; Medulloblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CheckMate 908
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 03 Aug 2023 Results assessing safety and efficacy of Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies published in the Neuro-Oncology
    • 10 Mar 2022 Status changed from active, no longer recruiting to completed.
    • 10 Mar 2022 This trial has been completed in Spain (Date of the global end of the trial : 17-Jan-2022), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top